Ionetix
Isotopes for today’s
diagnostics and
tomorrow’s
therapies.
Actinium-225 and astatine-211 alpha therapy programs. Ionetix's point-of-care PET sites. All powered by Ionetix's proprietary know-how and expertise.
Ionetix makes medical isotopes, and the machines that produce them.
On the diagnostic side, PET radiopharmaceuticals manufactured at FDA-approved sites built close to the scanner, because an N-13 ammonia dose has a usable life of about 45 minutes and cannot be shipped.
On the therapeutic side, no carrier added alpha emitters supplied to drug development programs from a purpose-built facility in Lansing, Michigan.
Behind both, decades of engineering and radiochemistry expertise, and the quality systems and logistics to support them.
Therapeutics
Alpha-emitting radioisotopes supplied to targeted therapy programs.
Shipping
- Half-life
- ~9.9 days
- Decay
- α
- Production
- Cyclotron
Ac-225
Produced from a radium-226 route, with no detectable actinium-227 co-produced. Supplied to programs in North America, Europe and Asia since 2024.
Shipping
- Half-life
- ~7.2 hr
- Decay
- α
- Production
- Cyclotron
At-211
A 7.2-hour half-life, supplied in solid or solution form. First North American commercial supply since September 2026.
Diagnostics
PET radiopharmaceuticals made minutes from the scanner.
Approved
- Half-life
- ~68 min
- Production
- Generator
Ga-68 PSMA-11
Gallium Ga-68 gozetotide for PSMA PET imaging. First ANDA approval granted to a commercial drug manufacturer, May 2026.
Partnering
- Half-life
- ~110 min
- Production
- Cyclotron
F-18
Produced on the ION-12SC cyclotron, available to partners holding a filing.
Shipping
- Half-life
- ~10 min
- Production
- Cyclotron
N-13 Ammonia
Cardiac PET tracer, produced on a cyclotron at every site in the network, under Ionetix's own ANDA.
Beyond Medicine
The same radioisotope engineering expertise, turned on nuclear waste.
A proton beam transmutes long-lived isotopes with half-lives reaching 1.5 million years into much shorter-lived isotopes, shortening the containment period required for waste streams. The heat produced can be captured to generate power.
Ionetix is a partner on a Department of Energy ARPA-E project under the NEWTON program to develop it.
-
Diagnostics
Diagnostic radiopharmaceuticals for precision imaging.
PET radiopharmaceuticals made minutes from the scanner.
Learn more about diagnostics -
Therapeutics
Alpha-emitting radioisotopes for targeted therapy.
Actinium-225 and astatine-211 from one Michigan facility.
Learn more about therapeutics -
Accelerator Platform
Cyclotron expertise and future applications of our technology.
Superconducting systems Ionetix designs, builds, and runs.
Learn more about accelerator platform
Contact